Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

3SBio Files to Begin Trial of Anemia Drug

publication date: Jan 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio Inc. applied to the SFDA to begin a registrational clinical trial for Feraheme™ (ferumoxytol) Injection, an IV treatment for iron deficiency anemia in patients with chronic kidney disease. 3SBio licensed the China rights for the drug from AMAG Pharmaceuticals last May, shortly before AMAG was granted approval for the product by the US FDA. More details...

Stock Symbols: (NSDQ: SSRX) (NSDQ: AMAG)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...